Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884

AIDS

Volumn 14, Issue 16, 2000, Pages 2495-2501

  Fletcher, Courtney V ^a   Acosta, Edward P ^a   Cheng, Hailong ^b   Haubrich, Richard ^c   Fischl, Margaret ^d   Raasch, Ralph ^e   Mills, Charlotte ^f   Hu, X Joan ^b   Katzenstein, David ^h   Remmel, Rory P ^g   Gulick, Roy M ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Antiretroviral drugs; Drug drug interactions; Pharmacokinetics

Indexed keywords

ADEFOVIR; CD4 ANTIGEN; DELAVIRDINE; NELFINAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

AGE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX RATIO;

ADENINE; ADULT; ANTI-HIV AGENTS; DELAVIRDINE; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; NELFINAVIR; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; SAQUINAVIR;

EID: 0033739530     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200011100-00011     Document Type: Article

References (17)

1. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society-USA Panel
2. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
3. Pharmacokinetic inter-actions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir
4. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir
5. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir or both in HIV-infected adults with virologic failure on indinavir - AIDS Clinical Trials Group Study 359
6. Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients
7. A simultaneous HPLC assay for quantification of indinavir, nelfinavir, ritonavir, and saquinavir in human plasma
8. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate
9. Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-infected patients
10. Saquinavir: Clinical pharmacology and efficacy
11. Microsomal metabolism of delavirdine: Evidence for mechanism-based inactivation of human cytochrome P450 3A
12. Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1infected patients
13. The drug transporter Pglycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
14. Human immuno-deficiency virus protease inhibitors serve as substrates for multidrug transporter MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters
15. Carrier mechanisms involved in the transepithelial transport of bis(POM)-PMEA and its metabolites across Caco-2 monolayers
16. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs